A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis

Trial Profile

A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Tocilizumab (Primary) ; Adalimumab
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms ADACTA
  • Sponsors Roche
  • Most Recent Events

    • 08 Jun 2017 Results assessing liver safety with long-term tocilizumab treatment for rheumatoid arthritis using pooled data (n= 4171) from five core phase 3 placebo-controlled studies (OPTION, TOWARD, LITHE, AMBITION, RADIATE), a clinical pharmacology study (NCT00365001), a phase 4 study (ADACTA) or long-term extension studies, published in the Arthritis and Rheumatology Journal.
    • 27 Nov 2015 Results published in the Annals of the Rheumatic Diseases (n = 324).
    • 18 Sep 2015 According to a Chugai Pharmaceutical media release, National Institute for Health and Clinical Excellence(NICE) has issued a positive Final Appraisal Determination(FAD) recommending tocilizumab [RoACTEMRA] monotherapy for use on the National Health Services.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top